1. Generics Bulletin
  2. >>Business

Novartis Sets Out Next Steps For Sandoz Spinoff

Parent Company Reveals Details Of Upcoming Process As Board Approves Separation

 
• By Dave Wallace

Following unanimous approval by the Novartis board of directors for the spinoff of Sandoz, the generics and biosimilars giant’s parent company has set out some key dates in the lead-up to separation later this year.

15 September pinned on calendar
15 September will be a key date for the Sandoz spinoff • Source: Shutterstock

Novartis has set out the next steps for its separation from Sandoz, after the parent company’s board unanimously endorsed the long-planned spinoff that will set up the generics and biosimilars giant as an independent standalone company.

Indicating that the separation from Sandoz is expected to be completed “in early Q4 2023,” Novartis said that the next step in the process following the board vote would see shareholders invited to vote on the proposed spin-off – and a related reduction of the share

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.